Related Experiment Video
Updated: Oct 13, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Structural modulation of p53TAD1-TAZ2 complex upon mutations and post-translational modification
Anamika Ghosh1, Debabani Ganguly2
1Department of Chemistry, Indian Institute of Engineering Science and Technology, Howrah, India.
Abstract:
The tumour suppressing p53 is a target for genetic alterations in human cancer. Native p53, found in latent state in cells, gets activated following various intracellular or extracellular responses. It plays imperative role in cell-cycle control, via growth-arrest, DNA repair and apoptosis, mainly regulated by post-translational modifications (PTM). However, the influence of PTMs on the activity of p53 is still under extensive experimental and computational study. There are numerous PTM sites in p53, which are reported to regulate its binding affinities with other proteins. Of the many, Thr18 at transactivational domain (TAD) of p53 is reported to amplify p53 activity upon phosphorylation. To understand the molecular basis of p53 recognition by its binding partner upon mutations and PTMs, we have exploited all atom molecular dynamic (MD) simulation of p53TAD1 bound to TAZ2 domain of p300. The MD simulation inferred that phosphorylated and mutated Thr18, as a phospho-mimic, bound with TAZ2, redistributed the charge environment of the interface, thereby modulating the stronger interactions with TAZ2 to enhance the binding efficiency. The electrostatic interactions due to different charge environment together with H-bonding and hydrophobic interaction dictate diverse binding approach between the two. The results of this computational study further explain the importance of the Thr18 as a PTM site in atomistic detail, hence shedding further light to the understanding of how PTMs are imperative for p53 activity to protect the cellular world.Communicated by Ramaswamy H. Sarma.
Insights
Post-translational modifications (PTMs) like phosphorylation at Thr18 amplify tumor suppressor p53 activity. Molecular dynamics simulations reveal how these PTMs enhance p53 binding to partner proteins, crucial for cellular protection.
Area of Science:
- Biochemistry
- Molecular Biology
- Computational Biology
Background:
- The tumor suppressor p53 is frequently altered in human cancers.
- p53 activity is regulated by post-translational modifications (PTMs), including phosphorylation.
- The precise impact of PTMs on p53 binding affinities is under investigation.
Purpose of the Study:
- To elucidate the molecular mechanisms by which PTMs and mutations at Thr18 influence p53 binding to its partners.
- To understand how these modifications affect p53's role in cancer.
Main Methods:
- All-atom molecular dynamic (MD) simulations were employed.
- Simulations focused on the p53 transactivation domain (p53TAD1) bound to the TAZ2 domain of p300.
- Analysis of charge redistribution, electrostatic interactions, H-bonding, and hydrophobic interactions.
Main Results:
- Phosphorylation and mutation at Thr18 act as a phospho-mimic, altering the charge environment at the p53-p300 interface.
- This redistribution enhances binding efficiency between p53TAD1 and TAZ2.
- Electrostatic, H-bonding, and hydrophobic interactions dictate the binding dynamics.
Conclusions:
- Thr18 is a critical PTM site that modulates p53 binding affinity and activity.
- Understanding these atomistic details is vital for comprehending p53's protective cellular functions.
- This study provides insights into how PTMs regulate p53's role in preventing cancer.
Related Concept Videos
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
DNA Damage can Stall the Cell Cycle

